Cellectar Biosciences, Inc. entered into a securities purchase agreement with accredited investors for a private placement offering of Series E-1 Convertible Voting Preferred Stock, Tranche A Warrants, and Tranche B Warrants for an aggregate offering price of $24.5 million.